相关实验视频

Updated: Feb 26, 2026

Characterization and Functional Prediction of Bacteria in Ovarian Tissues

Characterization and Functional Prediction of Bacteria in Ovarian Tissues

Published on: October 23, 2021

宫和阴道样本中的体质突变:评估它们在卵巢癌检测和预后中的作用

Beatriz Pelegrina¹, Sonia Paytubi¹, Yolanda Benavente¹

¹Cancer Epidemiology Research Programme, Catalan Institute of Oncology. IDIBELL. Av Gran Vía 199-203, 08908 L'Hospitalet de Llobregat, Barcelona, Spain; Consortium for Biomedical Research in Epidemiology and Public Health - CIBERESP. Carlos III Institute of Health. Av. De Monforte de Lemos 5, 28029, Madrid, Spain.

Translational oncology

|February 24, 2026

概括

帕普检查样本中的DNA体变异显示卵巢癌检测的诊断能力有限. 然而,这些变异可能表明整体存活率较低,这表明预后价值和需要进一步研究.

科学领域:

妇科瘤学妇科瘤学
分子诊断学分子诊断学
癌症基因组学癌症基因组学

背景情况:

由于缺乏早期症状和有效查,卵巢癌的诊断往往会延迟.
在宫和阴道样本中研究DNA体变异为改善卵巢癌检测和预后提供了潜在的途径.

研究的目的:

评估DNA体变异在宫和阴道样本中用于检测卵巢癌的实用性.
评估这些变异在患者存活率方面的预后意义.

主要方法:

一项病例控制研究使用了具有分子标识符的下一代测序 (NGS).
分析了来自卵巢癌患者和对照者的巴氏涂片,阴道自取样本,子宫内膜吸收和瘤样本.

主要成果:

在25.6%的卵巢癌巴氏涂片样本中发现了致病变体,在对照组中发现了33.3% (66.7%的特异性).
在14.3%的阴道样本,77.8%的子宫内膜吸收和69.2%的瘤样本中检测到变异.
在帕普样中存在变异与较差的整体存活率相关 (HR=4.27,P=0.041).

结论:

宫阴道样本中的DNA体变异对卵巢癌的诊断价值有限.
这些变异可能具有预后意义,需要进一步研究.
未来的策略可以将分子标记物与其他方法相结合,以提高早期检测.

关键词:

早期检测早期检测突变突变突变突变突变国家储备系统 (NGS)卵巢癌是发生在卵巢中的癌症.帕普检查的涂抹检查.抽取阴道样本进行检查.

更多相关视频

An Orthotopic Model of Serous Ovarian Cancer in Immunocompetent Mice for in vivo Tumor Imaging and Monitoring of Tumor Immune Responses

An Orthotopic Model of Serous Ovarian Cancer in Immunocompetent Mice for in vivo Tumor Imaging and Monitoring of Tumor Immune Responses

Published on: November 28, 2010

Method for Obtaining Primary Ovarian Cancer Cells From Solid Specimens

Method for Obtaining Primary Ovarian Cancer Cells From Solid Specimens

Published on: February 4, 2014

相关概念视频

Cancers Originate from Somatic Mutations in a Single Cell

Cancers Originate from Somatic Mutations in a Single Cell

Cancer arises from mutations in the critical genes that allow healthy cells to escape cell cycle regulation and acquire the ability to proliferate indefinitely. Though originating from a single mutation event in one of the originator cells, cancer progresses when the mutant cell lines continue to gain more and more mutations, and finally, become malignant. For example, chronic myelogenous leukemia (CML) develops initially as a non-lethal increase in white blood cells, which progressively...